Covalent drugs have been used to treat diseases for more than a century, but tools that
facilitate the rational design of covalent drugs have emerged more recently. The purposeful …

Ninety percent of clinical drug development fails despite implementation of many successful
strategies, which raised the question whether certain aspects in target validation and drug …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …

Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Herein, we present the long-term follow-up of the randomized E1912 trial comparing the
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …

Bruton tyrosine kinase (BTK) inhibitors have improved chronic lymphocytic leukemia (CLL)
outcomes and offer a chemotherapyfree option [1]. The BTK inhibitor ibrutinib, alone or with …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …